12:00 AM
Mar 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GGF2: Phase I data

A double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial in 40 patients with advanced heart failure showed that IV GGF2 was generally well tolerated up to the maximum tolerated dose (MTD) of 0.75 mg/kg. There was 1 dose-limiting toxicity (DLT) of hepatotoxicity and 1 case of uroepithelial carcinoma, a form of bladder cancer. Acorda said the patient's baseline urinalysis showed the presence of red blood...

Read the full 299 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >